The structural MRI markers and cognitive decline in prodromal Alzheimer’s disease: a 2-year longitudinal study

Alzheimer’s disease (AD) is a chronic neurodegenerative disease clinically characterized by the patient’s cognitive ability worsening and having an impairment for daily activities. It is pathologically characterized by amyloid-beta (Aβ) plaques levels and presence of neurofibrillary tangles (1,2). Mild cognitive impairment (MCI) is an intermediate stage between cognitively normal status and AD (3)